Company Release, 22 December 2022 at 4:15 p.m. (EET)

The Board of Directors of Nightingale Health Plc has on 30 November 2022 approved a request of a shareholder to convert 201,670 Series A shares of Nightingale Health Plc to Series B shares in accordance with Article 5 in the Articles of Association.

As a result of conversion of shares, the number of the company’s Series A shares is 20,585,924, Series B shares is 39,093,770 and EMP shares is 1,238,765. The conversion does not affect the total amount of shares which is 60,918,459. The number of votes of the company's shares is after the conversion 244,953,010.

The conversions of shares were registered in the Trade Register on 22 December 2022. The converted shares will be listed on the Nasdaq First North Growth Market Finland marketplace together with the old shares as of 23 December 2022.


For further information, please contact:

Teemu Suna, CEO

Certified Adviser:
Oaklins Merasco Ltd, tel. +358 9 6129 670

About Nightingale Health

Nightingale Health is The Preventative Health Company. Staying healthy is one of the top priorities in life. Our health has a profound impact on our quality of life, and it’s also strongly connected to the lives of those close to us. Nightingale Health enables prevention by combining the power of our in-house developed, advanced blood analysis technology with unprecedented access to global health repositories and world-leading medical research. With this combination, we go beyond the traditional healthcare and wellbeing tools: We provide the scientific connection to multiple health and disease outcomes and the ability to predict future healthy years.


Nasdaq Helsinki Ltd

Principal Media